Welcome to SYNIMMUNE

SYNIMMUNE GmbH is a biotechnology company dedicated to the development of innovative and effective mono- and bispecific anti-tumor antibodies for the treatment of patients suffering from life-threatening diseases, with a focus on orphan hematopoietic malignancies. SYNIMMUNE’s lead product candidate is the antibody FLYSYN, which is currently in a first-in-human phase I clinical study in acute myeloid leukemia (AML). SYNIMMUNE GmbH is a spin-off of the Department of Immunology of the University of Tuebingen. The Company is financed by grants from the German Ministry of Education and Research (BMBF) within its GO-Bio program as well as investments by the German KfW and private equity.

NEWS

PRESS RELEASE

 

SYNIMMUNE GmbH Initiates First-in-Human Study of Fc-optimized Antibody FLYSYN for the Treatment of Acute Myeloid Leukemia

 

DOWNLOAD

Contact:

Synimmune GmbH:

Dr. Martin Steiner

CEO

+49 7071 770 8382

steiner[at]synimmune.de

 

Closing of Second Financing

23. October 2015 – SYNIMMUNE GmbH has closed a second financing round with its existing investors German Kreditanstalt für Wiederaufbau (KfW) and Synimmune Equity Ltd. The Company will establish an Advisory Board, which will be comprised of Michael Kring, CEO of High Tech Corporate Services, as Chairman, and of Prof. Hans-Georg Rammensee, Founder of SYNIMMUNE GmbH and Head of the Department of Immunology at the University of Tuebingen and a representative of Synimmune Equity. Dr. Martin Steiner, independent consultant for biotechnology companies and former founder and CEO of two biotechnology companies will join SYNIMMUNE as General Manager and CEO.

Closing of First Financing

25. January 2012 - SYNIMMUNE GmbH, a spin-off from the Department of Immunology of the University of Tuebingen, has closed its first financing round with German Kreditanstalt für Wiederaufbau (KfW) and Synimmune Equity. In addition, SYNIMMUNE received a grant from the German Ministry of Education and Research (BMBF) within its GO-Bio program. The funds raised should be sufficient to finance GMP manufacturing of SYNIMMUNE’s lead product FLYSYN and its preclinical development as well as to further develop SYNIMMUNE’s technology platform for bispecific antibodies.

Foundation of SYNIMMUNE GmbH

7. July 2010 – SYNIMMUNE GmbH was founded by Dr. Steffen Aulwurm, Dr. Andreas Herrmann, Dr. Ludger Große-Hovest, Prof. Gundram Jung and Prof. Hans-Georg Rammensee. SYNIMMUNE is a spin-off in the course of an ongoing research project at the Department of Immunology at the University of Tuebingen funded by the German Ministry of Education and research (BMBF) within its GO-Bio program. SYNIMMUNE GmbH will focus on the development of innovative and effective anti-tumor antibodies for the treatment of patients suffering from life-threatening diseases and plans to raise funds from private investors and further research grants.